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Abstract: Seaweeds are an underexploited and potentially sustainable crop which offer a rich source
of bioactive compounds, including novel complex polysaccharides, polyphenols, fatty acids, and
carotenoids. The purported efficacies of these phytochemicals have led to potential functional food
and nutraceutical applications which aim to protect against cardiometabolic and inflammatory risk
factors associated with non-communicable diseases, such as obesity, type 2 diabetes, metabolic
syndrome, cardiovascular disease, inflammatory bowel disease, and some cancers. Concurrent
understanding that perturbations of gut microbial composition and metabolic function manifest
throughout health and disease has led to dietary strategies, such as prebiotics, which exploit the
diet-host-microbe paradigm to modulate the gut microbiota, such that host health is maintained or
improved. The prebiotic definition was recently updated to “a substrate that is selectively utilised by
host microorganisms conferring a health benefit”, which, given that previous discussion regarding
seaweed prebiotics has focused upon saccharolytic fermentation, an opportunity is presented to
explore how non-complex polysaccharide components from seaweeds may be metabolised by host
microbial populations to benefit host health. Thus, this review provides an innovative approach
to consider how the gut microbiota may utilise seaweed phytochemicals, such as polyphenols,
polyunsaturated fatty acids, and carotenoids, and provides an updated discussion regarding the
catabolism of seaweed-derived complex polysaccharides with potential prebiotic activity. Additional
in vitro screening studies and in vivo animal studies are needed to identify potential prebiotics
from seaweeds, alongside untargeted metabolomics to decipher microbial-derived metabolites from
seaweeds. Furthermore, controlled human intervention studies with health-related end points to
elucidate prebiotic efficacy are required.
Keywords: seaweed; gut microbiota; prebiotics; dietary fibre; complex polysaccharides; polyphenols;
polyunsaturated fatty acids; carotenoids; phytochemicals
1. Introduction
Seaweeds are an underexploited and sustainable crop which offer a rich source of bioactive
compounds, including novel dietary fibres, polyphenols, fatty acids, and carotenoids [1,2].
Epidemiological evidence comparing Japanese and Western diets have correlated seaweed consumption
(5.3 g/day in Japan) with decreased incidence of chronic disease [3], while the purported efficacies of
seaweed phytochemicals have led to potential functional food and nutraceutical applications which aim
to protect against cardiometabolic and inflammatory risk factors associated with non-communicable
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diseases, such as obesity, type two diabetes, metabolic syndrome, cardiovascular disease, inflammatory
bowel disease, and some cancers [1].
Current understanding of mutualistic diet-host-microbe interactions has generated efforts to
exploit diet to maintain health status, and to prevent or overcome non-communicable diseases, where an
imbalance of gut microbiota composition and metabolic function manifests during the onset and
pathophysiology of gastrointestinal, neurological, and cardio-metabolic diseases, often congruent
with intestinal inflammation and compromised gut barrier function [4,5]. As such, it has become
pertinent to explore dietary strategies which modulate gut microbial composition and function to
improve host health. This includes the use of prebiotics as fermentable substrates to enable selective
gut commensal metabolism.
The prebiotic definition was recently updated to “a substrate that is selectively utilised by
host microorganisms conferring a health benefit” [6], which includes the inhibition of pathogens,
immune system activation, and vitamin synthesis and provides opportunity to explore the
prebiotic efficacy of non-complex polysaccharide components such polyphenols, phytochemicals,
and polyunsaturated fatty acids (PUFAs) [6]. It is also recognised that other microbial species have the
potential to catabolise prebiotics, besides the classical examples of Bifidobacterium and Lactobacillus [6],
courtesy of culture-independent techniques, such as 16S rRNA next generation sequencing and whole
genome shotgun metagenomic sequencing which have provided taxonomic classification to identify
microbial abundance/diversity and inferred or identified metabolic function [7].
Given that previous discussion regarding the prebiotic potential of seaweed components has
focused solely upon the saccharolytic fermentation of complex polysaccharides and the physiological
effects of short chain fatty acid metabolites (SCFAs) [3,8,9], scope exists to explore the prebiotic potential
of other phytochemical components derived from seaweeds, namely polyphenols, carotenoids,
and PUFAs, applicable to both human and animal health.
This review aims to provide an updated discussion regarding the fermentation and potential
prebiotic effect of seaweed polysaccharides and oligosaccharides, based on recent evidence from in vitro
fermentation studies and in vivo animal models, and to postulate how other seaweed phytochemicals,
such as polyphenols, PUFAs, and carotenoids, may interact with the gut microbiota to manipulate
microbial composition and/or function to elicit bioactivities pertained to a prebiotic. The latter provides
new opportunities to complete prebiotic screening studies using in vitro techniques and pre-clinical
animal models to understand how parent compound biotransformation into endogenously-derived
or gut microbiota-derived metabolites impact bioaccessibility and bioavailability to influence gut
microbial community structure and function, conducive to a prebiotic effect. Evidence from clinical
trials with health-related end-points and mechanistic insight is imperative to substantiate health claims
associated with a prebiotic effect.
2. Complex Polysaccharides
Seaweeds contain 2.97–71.4% complex polysaccharides [2,3], which include alginate, fucoidan,
and laminarin in brown seaweeds; xylan and sulphated galactans, such as agar, carrageenan,
and porphyran in red seaweeds; whilst ulvan and xylan are found in green seaweeds.
The monosaccharide composition of the major brown, red, and green seaweed glycans are presented in
Table 1, Table 2, Table 3, respectively. Whilst no human study to date has explored prebiotic sources
from seaweeds, several in vitro studies [10–13], and in vivo animal studies [14,15], have explored the
prebiotic potential seaweeds and their polysaccharide components.
Seaweed polysaccharides are atypical in structure to terrestrial glycans, and are understood to
resist gastric acidity, host digestive enzymes, and gastrointestinal absorption [8]. Seaweed glycans
may, therefore, serve as fermentation substrates for specific gut microbial populations or facilitate
substrate cross-feeding of partially broken-down intermediates, such as oligosaccharides and metabolic
cross-feeding of SCFAs to cause indirect proliferation of specific bacteria [16–20]. The physiological
effects of SCFAs, primarily acetate, propionate, and butyrate, include the reduction of luminal pH to
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inhibit pathogens, the provision of energy sources to colonocytes, and the activation of free fatty acid
receptors; where acetate and propionate are ligands for anorexigenic pathways in appetite regulation
and can inhibit the rate limiting step of hepatic cholesterol synthesis via 3-hydroxy-3-methylglutaryl
CoA reductase inhibition [21–23].
To facilitate saccharolytic fermentation in the colon, the gut microbiota must express functional
carbohydrate active enzymes (CAZymes) to catabolise seaweed glycans as carbon sources within
the colonic digesta. The repertoire of CAZymes expressed by the human gut microbiota
includes glycoside hydrolase and polysaccharide lyase families to facilitate degradation via
hydrolysis and elimination reactions, respectively [24–26]. Whole genome sequencing has previously
identified gene clusters which encode the catabolic machinery responsible for the breakdown
of prebiotics, which includes the CAZyme families responsible for the catabolism of inulin,
lactulose, fructo-oligosaccharides, xylo-oligosaccharides, and galacto-oligosaccharides by human
gut commensal strains, including Bifidobacterium longum NCC2705, Bifidobacterium adolescentis ATCC
15703, Streptococcus thermophilus LMD9, Eubacterium rectale ATCC 33656, Bacteroides vulgatus ATCC
8482, and Fecalibacterium prausnitzii KLE1255 [27].
Based on open source data from the Carbohydrate-Active enZYmes Database [28], Tables 1–3
detail the CAZyme families which may exert specificity for seaweed glycans and highlights the gut
bacterial populations which have demonstrable evidence for seaweed glycan utilisation. This is
dominated by Bacteroides, which have extensive glycolytic versatility [26,29]. This may explain why
in vitro batch culture fermentation data of seaweeds and seaweed glycans indicate the proliferation of
Bacteroides; whilst the degradation of complex seaweed glycans by Bacteroides could also facilitate the
cross-feeding of oligosaccharides, monosaccharides, and SCFAs for gut commensals deemed beneficial
to health, including Bifidobacterium.
In vitro fermentation studies are frequently used as screening tools to model colonic fermentation
and determine substrate utilisation by an ex vivo faecal inoculum, with seaweed as a sole carbon
source. An overview of recent in vitro fermentation studies which have evaluated the fermentation
of whole seaweeds or extracted complex polysaccharide components by the human gut microbiota
is presented in Table 4 (brown seaweeds), Table 5 (red seaweeds), and Table 6 (green seaweeds).
These tables include differences in study methodologies, for example, test substrate dosage; the use of
an in vitro digestion before the fermentation experiment (declared within the methods section of the
cited research paper); how the inoculum was prepared; duration of the faecal fermentation experiment;
microbial enumeration method; and the analytical technique used to ascertain metabolite changes
during the fermentation. The use of an in vitro digestion before in vitro fermentation is often used
to determine whether a substrate is resistant to endogenous digestive enzymes and small intestinal
absorption, and to provide the fraction of a dietary component which is bioaccessible in the colon [30].
The lack of an in vitro digestion before fermentation experiments may cause false positive results,
given that low molecular weight components present in seaweed extracts, normally absorbed in the
small intestine, are used as fermentation substrates for the ex vivo microbiota. Table 7 highlights
data from in vivo rodent studies which have evaluated the potential prebiotic effect of seaweeds and
seaweed glycans.
Mar. Drugs 2019, 17, 327 4 of 35
Table 1. Potential degradation of brown seaweed glycans by the human gut microbiota.
Carbohydrate Carbohydrate-ActiveEnzyme (CAZyme)
Evidenced Glycolytic
Bacteria Reference
Alginate 1,4-β-d-mannuronic acid
α-l-guluronic acid
PL6 Alginate lyase
PL6 MG-specific alginate lyase
Bacteroides clarus
Bacteroides eggerthii
PL15 Alginate lyase
PL15 Oligoalginate lyase
Bacteroides ovatus
Bacteroides thetaiotaomicron
Bacteroides xylanisolvens
[31–36]
PL17 Alginate lyase
PL17 Oligoalginate lyase
Bacteroides clarus
Bacteroides eggerthii
Fucoidan
Sulphated
1,2-1,3-1,4-α-l-fucose
GH29 α-l-fucosidase
GH29 α-1,3/1,4-l-fucosidase Not determined [37]
GH95 α-l-fucosidase
GH95 α-1,2-l-fucosidase
Laminarin 1,3-1,6-β-glucose
GH16 β-glucanase
GH16 β-1,3-1,4-glucanase
GH16 endo-1,3-β-glucanase
Bacteroides distasonis
Bacteroides fragilis
Bacteroides thetaiotaomicron
[10,38]
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified
using the Carbohydrate-Active enZYmes Database [28].
Table 2. Potential degradation of red seaweed glycans by the human gut microbiota.
Carbohydrate Carbohydrate-Active Enzyme(CAZyme)
Evidenced
Glycolytic
Bacteria
Reference
Agar
(Galactan)
1,3-β-d-galactose
1,4-3,6-anhydro-α-l-galactose
GH2 β-galactosidase
Bacteroidetes
plebeius [39–42]
GH16 β-agarase
GH86 β-agarase
GH117
1,3-α-3,6-anhydro-l-galactosidase
Carrageenan
(Galactan)
1,4-β-d-galactose
1,3-α-d-galactose
3,6-anhydro-d-galactose
GH2 β-galactosidase Bacteroides plebeius [41,43]
GH117
1,3-α-3,6-anhydro-l-galactosidase
Porphyran
(Galactan)
Sulphated 1,3-β-d-galactose
1,4-α-l-galactose-6-sulfate
3,6-anhydro-α-l-galactose
GH16 β-porphyranase
GH86 β-porphyranase Bacteroides plebeius [41,44,45]
Xylan 1,3-1,4-β-d-xylose
GH3 xylan 1,4-β-xylosidase
Not determined [46–49]
GH5 endo-1,4-β-xylanase
GH10 endo-1,4-β-xylanase
GH10 endo-1,3-β-xylanase
GH11 endo-β-1,4-xylanase
GH11 endo-β-1,3-xylanase
GH43 β-xylosidase
GH43 xylanase
GH43 β-1,3-xylosidase
GH67 xylan α-1,2-glucuronidase
GH115 xylan α-1,2-glucuronidase
CE1−CE7 and CE12 acetyl
xylanesterases
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified
using the Carbohydrate-Active enZYmes Database [28].
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Table 3. Potential degradation of green seaweed glycans by the human gut microbiota.
Carbohydrate Carbohydrate-ActiveEnzyme (CAZyme)
Evidenced Glycolytic
Bacteria Reference
Ulvan
Sulphated
1,4-β-d-Glucuronic acid
α-l-Rhamnose
1,4-β-d-xyloglucan
GH78 α-l-rhamnosidase
Not determined [50,51]
GH145 α-l-rhamnosidase
Xylan 1,3-β-d-xylose
GH10 endo-1,3-β-xylanase,
Not determined [52]GH11 endo-β-1,3-xylanase
GH43 β-1,3-xylosidase
PL, Polysaccharide Lyase family; GH, Glycoside Hydrolase family. Potential glycolytic bacteria were identified
using the Carbohydrate-Active enZYmes Database [28].
2.1. Brown Seaweed Polysaccharides
Brown seaweeds are commonly used as food ingredients owing to their commercial abundance [53].
The anti-obesogenic effects of brown seaweeds are reported in mice, where supplementation of 5%
(w/w) Saccorhiza polyschides extract, containing 12% dietary fibre, reduced body weight gain and fat mass
of mice with diet-induced obesity [54]. The anti-obesogenic effect was attributed to the fermentation
of alginate and fucoidan complex polysaccharide components, owing to reduced microbial bile salt
hydrolase activity; however, no gut microbial compositional data were provided. Elsewhere, the in vitro
evidence (Table 4) indicates that whole brown seaweeds and their extracted complex polysaccharide
components are fermented by the ex vivo faecal microbiota, with increased production of acetate,
propionate, butyrate, and total SCFAs reported during fermentation experiments. A corresponding
increase in populations, such as Bifidobacterium, Bacteroides, Lactobacillus, Roseburia, Parasutterella,
Fusicatenibacter, Coprococcus, Fecalibacterium is also reported [55–57].
2.1.1. Alginate
Alginates are composed of 1,4-linked α-l-guluronic (G) and β-d-mannuronic acid (M) residues to
form GM, GG and MM blocks, and represent 17−45% dry weight of brown seaweeds [58]. The colloidal
properties of alginates have wide application in food processing, biotechnology, medicine and
pharmaceutical industries [59], while degraded sodium alginate is an approved item of “foods with
specified uses”, under the categories of “Foods that act on cholesterol plus gastrointestinal conditions”
and “Foods that act on blood cholesterol levels” in Japan [60]. The presence of water soluble alginate
oligosaccharides in the faeces of pigs fed alginate is indicative of alginate lyase activity by the luminal
or mucus adherent gut microbiota [61], although an adaptation period of > 39 days is reported for the
degradation of G blocks by the porcine microbiota whilst M blocks are readily degraded [62].
The capacity for alginate to modulate the gut microbiota of Japanese individuals was highlighted
over 20 years ago [63], where alginate supplementation (30 kDa, 10 g/day, n = 8) significantly
increased faecal Bifidobacterium populations in healthy male volunteers after both one and two weeks,
alongside significantly increased acetic and propionic acids after two weeks. Deleterious metabolites,
including faecal sulphide, phenol, p-cresol, indole, ammonia and skatole were significantly reduced
compared to the control (free living) diet. Notably, faecal Bifidobacterium counts and SCFA concentrations
returned to baseline in the week after alginate diet cessation, which highlights the transient nature of
the gut microbiota and the need for greater powered long-term human intervention studies.
Subsequent in vitro fermentation studies have indicated that alginate is fermented by
the human gut microbiota, for example, a 24 h in vitro fermentation of a 212 kDa alginate
increased total bacterial populations, although no statistical increase in individual Bifidobacterium,
Bacteroides/Prevotella, Lactobacillus/Enterococcus, Eubacterium rectale/Clostridium coccoides, or Clostridium
histolyticum populations were observed [11]. Acetic acid, propionic acid and total SCFAs were
significantly increased after 24 h fermentation with the 212 kDa alginate, while alginate of 97 kDa
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increased total SCFA and acetate production after 10 h of fermentation. Alginates of 38 kDa, and 97 kDa
did not change microbial abundance, although the authors could not correlate molecular weight with
fermentation patterns.
Alginate oligosaccharides (AOS) (~3.5 kDa) can be obtained via acidic or enzymatic hydrolysis
of alginate polysaccharides [58], and enzymatically derived AOS has promoted the growth of
Bifidobacterium bifidum ATCC 29521, Bifidobacterium longum SMU 27001 and Lactobacilli, in vitro [64,65].
Supplementation of 2.5% AOS for two weeks significantly increased faecal Bifidobacterium.
in rats compared to control and 5% FOS supplemented diets (13-fold and 4.7-fold increase,
respectively), while faecal Lactobacillus were 5-fold greater in rats who consumed AOS compared
to FOS. Enterobacteriaceae and Enterococcus populations were significantly decreased following
AOS supplementation. Elsewhere, the hydrolysis of alginate, mannuronic acid oligosaccharides
(MO) and guluronic oligosaccharides (GO) during a 48 h batch culture fermentation with the
faecal microbiota of Chinese individuals demonstrated increased production of acetate, propionate,
butyrate, and total SCFAs compared to the substrate-free control, where GO generated the greatest
increase [36]. Subsequent strain isolation from the stools of individuals who demonstrated alginate
degradation during fermentation identified Bacteroides xylanisovlens G25, Bacteroides thetaiotomicron
A12, Bacteroides ovatus A9, and Bacteroides ovatus G19 as strains capable of hydrolysing alginate
and AOS, where Bacteroides ovatus G19 expressed α-1,4-guluronanlyase and β-1,4-mannuronanlyase
CAZymes [34].
A Bacteroides xylanisolvens strain with 99% similarity to Bacteroides xylanisolvens XB1A was recently
isolated from the stool of a Chinese individual and the alginate lyase gene expressed was 100%
homologous to the alginate lyase of Bacteroides ovatus strain ATCC 8483 [33]. The preceding in vitro
fermentation study demonstrated increased production of acetate, propionate, butyrate, and total
SCFAs compared to the soluble starch control vessel following a 72 h fermentation of alginate.
Alginate lyase depolymerises alginate polysaccharides to lower molecular weight oligosaccharides
via β-elimination, and is most commonly expressed by marine bacteria, including Flammeovirga,
Vibrio, Pseudoalteromonas, Glaciecola chathamensis S18K6, and Zobellia galactanivorans [65–69], while the
terrestrial bacteria Paenibacillus sp. Strain MY03 was recently reported to possess genes encoding
alginate lyase and agarase enzymes [70]. The acquisition of genes encoding alginate lyase enzymes
by human gut Bacteroides is a suggested consequence of horizontal gene transfer from the marine
environment [31,71], where seaweed consumption may have provided a vector to exert a selective
pressure to induce diet-driven adaptations of the gut microbiota [35,72–76]. Recent work by Matthieu
et al. [35] suggests that an alginate degradation system within the genome of human gut Bacteroides
was a result of ancient acquisition, where the polysaccharide utilisation loci encodes PL6 and PL17
alginate lyase enzymes and hypothetical proteins responsible for alginate recognition, internalisation,
and catabolism, including bacterial ABC transporter proteins to facilitate alginate uptake across
the bacterial membrane [77]. Nevertheless, in vivo rodent studies have demonstrated that seaweed
glycans are fermented even though animals have never been exposed to dietary seaweeds before the
intervention, which suggests that the gut microbiome contains genes for CAZymes which can degrade
seaweed glycans when expressed.
2.1.2. Laminarin
Laminarin is a water-soluble storage polysaccharide consisting of 1,3- or 1,6-β-glucose with an
average molecular weight of 5 kDa [78] and accounts for 10–35% of the dry weight of brown
seaweeds [58]. One in vitro batch culture fermentation of laminarin demonstrated increased
Bifidobacteria and Bacteroides after 24 h [79], while another demonstrated increased propionate and
butyrate production after 24 h [14]. A subsequent in vivo rat study (143 mg laminarin per kg body
weight per day for 14 days) indicated that laminarin was not selectively fermented by Lactobacillus and
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Bifidobacterium, but could modify jejunal, ileal, caecal and colonic mucus composition, secretion,
and metabolism to protect against bacterial translocation. The authors suggest that increased
luminal acidity and/or catabolism of laminarin by mucolytic commensals could elicit such effects,
which corroborates the evidence that a complex polysaccharide-rich diet maintains mucus layer
integrity to promote gut barrier function [80,81]. Future studies regarding intestinal mucus modulation
by laminarin may wish to characterise gut microbiota compositional and functional changes following
laminarin ingestion, to detect the abundance and metabolic activity of glycan degraders, such as
Bacteroides [82,83] or mucolytic species associated with health, such as Akkermansia muciniphila or
Ruminococcus [84,85]. Elsewhere, laminarin increased L-cell GLP-1 secretion to attenuate diet-induced
obesity in mice, and improved glucose homeostasis and insulin sensitivity [86]. The authors suggested
that the observed cytosolic Ca2+ cascade caused GLP-1 secretion, which is in agreement with GPR41/43
receptor activation by SCFAs produced by gut microbial fermentation [87,88], however, data obtained
to assess laminarin-induced changes to gut microbiota composition and metabolic output is needed to
ascribe a prebiotic effect in this study.
The abundance of glycoside hydrolase and β-glucosidase enzymes expressed by the human gut
microbiota may have the capacity to catabolise laminarin [24,89–91], for example, a Bacteroides
cellulosyliticus WH2 human gut isolate was able to grow on laminarin-supplemented minimal
media in vitro, (incidentally it did not grow on alginate, carrageenan, or porphyran) [92]; however,
the molecular mechanisms by which human gut Bacteroides breakdown laminarin are likely distinct
from those responsible for the degradation of mix linked β 1,3- 1,4- glucans, such as those found in
cereals (e.g., by BoGH16MLG) [93].
2.1.3. Fucoidan
Fucoidans are water soluble polysaccharides composed of sulphated 1,2- or 1,3- or 1,4-α-l-fucose
which exist as structural polysaccharides in brown seaweeds and occupy 5–20% of algal dry
weight [58,94]. The structural heterogeneity of fucoidan encompasses varying degrees of branching,
sulphate content, polydispersity, and irregular monomer patterns, which can include fucose, uronic acid,
galactose, xylose, arabinose, mannose, and glucose residues [9,59,95].
A recent in vitro fermentation study of fucoidan (<30 kDa) extracted from Laminaria japonica
demonstrated a greater increase in Bifidobacterium and Lactobacillus following 24 h and 48 h fermentation
relative to >30 kDa fucoidan [12], while fucoidan from Ascophyllum nodosum (1330 kDa) and Laminaria
japonica (310 kDa) were shown to increase Lactobacillus and Ruminococcaceae, respectively, in the caecal
microbiota of mice gavaged with 100 mg/kg/day [96]. Fucoidan also reduced serum LPS-binding
protein levels in this study—indicative of a reduced antigen load and reduced inflammatory response.
In contrast, fucoidan with a fucose-rich and highly sulphated fucoidan extracted from Cladosiphon
okamuranus was not fermented by the rat gut microbiota [97].
While the purported bioactivities of fucoidan include anti-obesogenic, anti-diabetic, anti-microbial,
and anti-cancer properties [98], there is limited evidence to implicate a role for the gut microbiota
with such bioactivities, and studies are needed to evaluate the structure-dependent fermentation of
fucoidan to ascribe a prebiotic effect. For the latter, this is surprising given the myriad of α-fucosidase
enzymes present in the human gut bacterial glycobiome.
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Table 4. In vitro fermentation of brown seaweeds with human faecal inoculum.
Seaweed Substrate Dose
Use of a Simulated
In Vitro Digestion
Before Fermentation?
Experimental
Parameters
Microbial
Enumeration Microbial Changes
Metabolomics
Analysis
Technique
Metabolite
Changes Reference
Ecklonia
radiata
Crude fraction (CF)
Phlorotannin-enriched
fraction (PF)
Low-molecular weight
polysaccharide fraction
(LPF)
High-molecular weight
polysaccharide fraction
(HPF)
1.5% (w/v)
Yes
CF = 71.5% digestible
PF = 87.3% digestible
LPF = 86.1% digestible
HPF = non-digestible
10% (w/v) pooled
inoculum
(n = 3)
24 h
qPCR
↑ Bifidobacterium ↑ Lactobacillus
(LPF)
↑ F. prausnitzii ↑ C. coccoides
↑ Firmicutes
(CF, LPF)
↑ Bacteroidetes ↑E. coli
(CF, PF, LPF, HPF)
↓ Enterococcus
(CF, PF)
GC-FID
↑Acetate
(CF)
↑Propionate
(CF, LPF, HPF)
↑ Butyrate
(CF, LPF, HPF)
↑ Total SCFA
(CF, LPF, HPF)
[56]
Ecklonia
radiata
Water extract (WE)
Acid extract (AE)
Celluclast enzyme extract
(CEE)
Alcalase enzyme extract
(AEE)
Free sugar fraction (FF)
Polysaccharide fraction
(PF)
Seaweed residue (SR)
Seaweed powder (SP)
1.5% (w/v) No–digestibilityunknown
10% (w/v) pooled
inoculum
(n = 3)
24 h
qPCR
= F. prausnitzii = C. leptum
= R. bromii ↑ Total bacteria
(CEE, AEE, WE, FF)
↑ Bifidobacterium ↑ Bacteroidetes
↑ Lactobacillus ↑ C. coccoides
(CEE)
↑ E. coli ↑ Enterocccus
(WE, AE, CEE, AEE, FF, PF, SP)
GC-FID
↑ Acetate
↑ Propionate
↑ Butyrate
(WE, AE, CEE, AEE,
FF, PF, SP)
↑ Total SCFA
[57]
Sargassum
muticum
Sargassum muticum
Alcalase enzyme extract
(SAE)
1% (w/v) Yes–non-digestible (%digestible undisclosed)
10% (w/v) single
inoculum
24 h
FISH
= Bifidobacterium
= Lactobacillus
= Clostridium histolticum
↑ Bacteroides/Prevotella
↓ C.coccoides/E.rectale
HPLC ↑ Total SCFA [99]
Sargassum
thunbergii Polysaccharide extract 0.3% (w/v)
No–digestibility
unknown
20% (w/v) pooled
inoculum
(n = 3)
24 h
16S rRNA
NGS
↑ Bacteroidetes
↑Bacteroidetes:Firmicutes ratio
↑ Bifidobacterium
↑ Roseburia
↑ Parasutterella
↑ Fusicatenibacter
↑ Coprococcus
↑ Fecalibacterium
GC-MS
↑ Acetate
↑ Propionate
↑ Butyrate
↑ Valerate
↑ Total SCFA
[55]
- Alginate 5% (w/v) No–digestibilityunknown
10% (w/v) single
inoculum
72 h
16S rRNA
DGGE
16S rRNA
NGS
↑Bacteroides GC-FID
↑ Propionate
↑ Butyrate
↑ Total SCFA
[33]
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Table 4. Cont.
-
Alginate (A)
Mannuronic acid
oligosaccharides (MO)
Guluronic acid
oligosaccharides (GO)
Propylene glycol alginate
sodium sulphate (PSS)
5 g/L (A)
8 g/L (MO, GO,
PSS)
No–digestibility
unknown
10% (w/v) single
inoculum
48 h
16S rRNA
DGGE
Detection of Bacteroides
xylanisolvens, Clostridium
clostridioforme/Clostridium
symbiosum, Bacteroides finegoldii,
Shigella flexneri/E.coli, E.fergusonii,
and Bacteroides ovatus
HPLC
A, MO, GO:
↑ Acetate
↑ Propionate
↑ Butyrate
↑ Total SCFA
[36]
Ascophyllum
nodosum
Sulphated polysaccharide
extract 9 mg/mL
Yes–non-digestible (%
digestible undisclosed)
10% (w/v)
pooled inoculum
(n = 4)
24 h
16S rRNA
NGS
↑Bacteroides
↑Phascolarctobacterium
↑ Oscillospira
↑ Fecalibacterium
GC-FID
↑ Acetate
↑ Propionate
↑ Butyrate
↑ Total SCFA
[100]
Laminaria
digitata
Crude polysaccharide
extract (CE)
Depolymerised crude
polysaccharide extract (DE)
1% (w/v) Yes–non-digestible (%digestible undisclosed)
20% (w/v) pooled
inoculum
(n = 3)
48 h
16S rRNA
NGS
↑Parabacteroides (CE, DE)
↑ Fibrobacter (CE)
↓ Streptococcus
↓ Ruminococcus
↑ Lachnospiraceae UC (DE)
↓ Peptostreptococcaceae IS (DE)
↑ Dialister (CE, DE)
↑ γ B38UC (CE)
GC-FID
↑ Acetate (CE, DE)
↑ Propionate (CE,
DE)
↑ Butyrate (CE, DE)
↑ Total SCFA (CE,
DE)
[101]
- Laminarin 1% (w/v) No–digestibilityunknown
10% (w/v) pooled
inoculum
(n = 5)
24 h
qPCR ↑Bifidobacterium↑Bacteroides HPLC
↑ Acetate
↑ Propionate
↑ Total SCFA
[79]
qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing;
HPLC, High Performance Liquid Chromaography; GC-MS, Gas Chromatography-Mass Spectrometry; 16S rRNA DGGE, 16S rRNA Denaturing Gradient Gel Electrophoresis; 16S rRNA
NGS, 16S rRNA Next Generation Sequencing; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromaography; 16S rRNA NGS,
16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; SCFA,
Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and
metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates
tested exerted the effect.
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2.2. Red Seaweed Polysaccharides
2.2.1. Galactans (Carrageenan, Agar, and Porphyran)
Red seaweeds, such as Gelidium spp. and Gracilaria spp., are used in the commercial production of
agar and carrageenan food additives, including thickening, stabilizing and encapsulation agents [53].
A summary of evidence from recent in vitro fermentation experiments using red seaweed-derived
substrates are presented in Table 5.
Carrageenans are composed of sulphated 1,4-β-d-galactose, 1,3-α-d-galactose, and 3,6-
anhydro-d-galactose [43], and constitutes 30−75% dry weight of red seaweeds [58]. In rats fed 2.5%
Chondrus crispus, of which carrageenan is a major polysaccharide component, faecal Bifidobacterium
breve, and acetate, propionate, and butyrate SCFAs were significantly increased alongside a significant
decrease in the pathogens Clostridium septicum and Streptococcus pneumonia, as compared to the
basal diet [15]. Furthermore, a 1:1 mixture of polysaccharide extracts from Kappaphycus alvarezii
(containing carrageenan) and Sargassum polycystum (brown seaweed) has lowered serum lipids in
rats [39]. In a study by Li et al. [34], β-carrageenase activity in a Bacteroides uniforms 38F6 isolate
complex of Bacteroides xylanisolvens and Escherichia coli hydrolysed κ-carrageenan oligosaccharides into
4-O-sulfate-d-galactose, κ-carratriose, κ-carrapentaose, and κ-carraheptaose, which could facilitate
cross-feeding to promote the growth of Bifidobacterium populations.
Agar is composed of sulphated 1,3-β-d-galactose and 1,4- 3,6-anhydro-α-l-galactose [40] and
can be fractionated into agarose and agaropectin [8]. Low molecular weight agar of 64.64 kDa has
demonstrated a bifidogenic effect alongside increased acetate and propionate SCFA concentrations
after 24 h in vitro fermentation with human stool inoculum [11], while mice fed with 2.5% (w/v)
neoagarose oligosaccharides for 7 days demonstrated increased caecal and faecal Lactobacillus and
Bifidobacterium [102]. The utilisation of agaro-oligosaccharides was noted in vitro by Bacteroides
uniforms L8, isolated from Chinese individuals, which secreted a β-agarase CAZyme to breakdown
agarooligosaccharides into agarotriose and subsequently facilitated the growth of Bifidobacterium
infantis and Bifidobacterium adolescentis via the cross feeding of agarotriose [103].
Porphyran is made up of sulphated 1,3-β-d-galactose, 1,4-α-l-galactose-6-sulfate and
3,6-anhydro-α-l-galactose [41,104,105]. An in vitro faecal fermentation study indicated that porphyran
did not significantly increase SCFAs, but stimulated Lactobacillus and Bacteroides populations [79].
While pure cultures of Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis,
Bifidobacterium adolescentis, but not Bifidobacterium bifidum, were able to ferment dried Porphyra
yezoensis (Nori), containing a low protein content (25%), whereas Nori with a high protein content
(41%) was not fermented [105]. It is likely that carbohydrate content was highest in the low protein
Nori, thus seasonal- and species-variation and in seaweed macronutrient content should be considered
a determinant factor for the fermentability of whole seaweeds [106–109].
Evidence for the horizontal transfer of genes for porphyranase and agarase CAZymes from the
marine bacteria, Zobellia galactanivorans, to Bacteroides plebeius of Japanese individuals is indicative
of diet-driven adaptations of the human gut microbiome [41,44]; however, the North American
counterparts in this study did not consume seaweeds and the gut microbiota of these individuals
did not express such CAZymes. This may mean that the fermentation of seaweed polysaccharides,
such as porphyran and agar, requires exposure to, and acquisition of, specific CAZymes usually present
in the marine environment [73]. Red seaweed galactans are emerging prebiotic candidates given
the commercial availability of red seaweed hydrocolloids and the potential gut modulatory effects
of oligosaccharides obtained from red seaweeds. Nevertheless, further in vivo evidence is needed,
given the purported pro-inflammatory effects of low molecular weight carrageenan [110–112].
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2.2.2. Xylan
Xylan, composed of 1,3-1,4-β-D-xylose, is a major constituent of red seaweeds, such as Palmaria
palmata [46]. A previous in vitro faecal fermentation study of xylan derived from P. palmata, reported that
xylose was fermented after six h alongside a 58:28:14 ratio of acetate, propionate, and butyrate SCFAs
(total SCFAs were 107 mM/L) [113]. This study did not ascertain bacterial compositional data, and thus
a knowledge gap is presented given that xylans and xylooligosaccharides (XOS) extracted from
terrestrial plants, such as wheat husks and maize, are mooted as potential prebiotics owing to evidence
of bifidogenesis, improved plasma lipid profile, and positive modulation of immune function markers
in healthy adults [114,115]. Given that human gut Bacteroides express a repertoire of xylanase and
xylosidase CAZymes [116], investigations regarding the capacity of the human gut microbiota to
catabolise red seaweed xylans and XOS are suggested.
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Table 5. In vitro fermentation of red seaweeds with human faecal inoculum.
Seaweed Substrate Dose
Use of a Simulated
in vitro Digestion
Before Fermentation?
Experimental
Parameters
Microbial
Enumeration Microbial Changes
Metabolomics
Analysis
Technique
Metabolite
Changes Reference
Kappaphycus
alvarezii
Whole
Seaweed (WS) 1% (w/v)
Yes–non-digestible
(% digestible
undisclosed)
10% (w/v) single
inoculum
24 h
FISH
↑Bifidobacterium
↓ Clostridium coccoides/
Eubacterium rectale
HPLC ↑ Total SCFA [13]
Osmundea
pinnatifida
Osmundea
pinnatifida
Viscozyme
extract (OVE)
1% (w/v)
Yes–non-digestible
(% digestible
undisclosed)
10% (w/v) single
inoculum
24 h
FISH
= Bifidobacterium
= Lactobacillus
= Clostridium histolticum
HPLC ↑Total SCFA [99]
Gracilaria
rubra
Polysaccharide
extract (PE)
1%
(w/v)
Yes–non-digestible
(% digestible
undisclosed)
10% (w/v) pooled
inoculum (n = 4)
24 h
16S rRNA
NGS
↑Bacteroides
↑Prevotella
↑Phascolarctobacterium
↓Firmicutes:Bacteroidetes
GC-FID
↑ Acetate
↑ Propionate
↑ Isobutyrate
↑ Total SCFA
[117]
- Porphyran 1% (w/v) No–digestibilityunknown
10% (w/v) pooled
inoculum (n = 5)
24 h
qPCR ↑Bifidobacterium↑Bacteroides HPLC
= Acetate
= Propionate
= Butyrate
= Total SCFA
[79]
FISH, Flourescence in situ Hybridisation; 16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector;
HPLC, High Performance Liquid Chromatography; SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control;
↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in
parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
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2.3. Green Seaweed Polysaccharides
Ulvan
Ulvans are water-soluble cell wall polysaccharides that account for 8–29% dry weight
of green seaweeds, and are composed of sulphated 1,3-α-l-rhamnose, 1,4-β-d-glucuronic acid,
and 1,4-β-d-xyloglucan [51]. Previous reports indicate that Ulva lactuca and ulvan polysaccharides
are poorly fermented by the human gut microbiota [8,95,118], while an in vitro fermentation study of
Enteromorpha spp. With a human faecal inoculum reported no difference in Enterococcus, Lactobacillus,
and Bifidobacterium populations compared to the control; only an increase in Enterobacter after
24 h and 48 h of fermentation (Table 6) [12]. In contrast, a recent in vitro faecal fermentation
study indicated that Ulvan stimulated the growth of Bifidobacterium and Lactobacillus populations
and promoted the production of lactate and acetate [79]. Further, a murine study showed that
Enteromorpha (EP) and Enteromorpha polysaccharides (PEP) ameliorated inflammation associated with
Loperamide-induced constipation in mice [119], where alpha diversity, Firmicutes, and Actinobacteria
were increased in the faecal microbiota of seaweed-supplemented mice compared to the constipated
control. Bacteroidetes and Proteobacteria were decreased, while Bacteroidales family S24-7 and
Prevotellaceae were increased in EP and PEP, respectively. Current evidence for the fermentation of green
seaweeds and their polysaccharides is limited and fermentation may require specific α-l-rhamnosidase
activity by gut commensals [50]. More experimental evidence is needed to understand the impact of
ulvans and ulvan-oligosaccharides in the human and animal diet.
2.4. Future Prospective–Obtaining Oligosaccharides
Enzyme technologies are reported to increase the extraction yield and reduce the molecular
weight of bioactive components obtained from seaweeds, with examples of enhanced prebiotic
activity when commercially available cellulases or seaweed-specific enzymes were used to hydrolyse
polysaccharides [99,120]. Despite limited commercial availability of seaweed-specific enzymes,
an avenue for functional oligosaccharide production is presented if efforts to develop commercially
viable saccharolytic enzymes from microorganisms (primarily marine). Examples of such glycoside
hydrolases include fucoidanase from Sphingomonas paucimobilis PF-1 [121]; ulvan lyase from
Alteromonas spp. [122] and the family Flavobacteriaceae [123]; β-agarase from Cellulophaga omnivescoria
W5C [124] and Cellvibrio PR1 [125]; alginate lyase from Flammeovirga [126], and Paenibacillus [70];
and laminarinase from Clostridiium thermocellum [127]. Factors which influence the stability and
efficacy of such hydrolytic enzymes may include metal ion interaction, or thermostability at the high
temperatures needed to prevent gelling of polysaccharides. Recent insight into the production of
agarose oligosaccharides and neoagarose oligosaccharides from agar exemplify this [128].
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Table 6. In vitro fermentation of green seaweeds with human faecal inoculum.
Seaweed Substrate Dose
Use of a Simulated
in vitro Digestion
Before Fermentation?
Experimental Parameters MicrobialEnumeration Microbial Changes
Metabolomics
Analysis
Technique
Metabolite
Changes Reference
Enteromorpha
prolifera
Polysaccharide
extract (PE)
0.2 g in 9.5 mL
0.8 g in 9.5mL
Yes-non-digestible
(% digestible
undisclosed)
10.5% (w/v) pooled inoculum (n = 3)
12, 24, and 48 h
Microbial
culture
↑Enterobacter (0.2
PE and 0.8 PE at
24 h and 48 h)
= Enterococcus
= Lactobacillus
= Bifidobacterium
GC-FID
= Acetate
= Butyrate
= Lactate
[12]
- Ulvan 1% (w/v) No-digestibilityunknown
10% (w/v) pooled inoculum (n = 5)
24 h qPCR
↑Bifidobacterium
↑Lactobacillus HPLC
↑ Acetate
↑ Lactate [79]
qPCR, Quantitative PCR; GC-FID, Gas Chromatography with Flame Ionisation Detector; HPLC, High Performance Liquid Chromatography; =, no statistical difference compared to the
control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the
substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
Table 7. Impact of seaweeds on the rodent gut microbiota.
Animal Substrate Dose Duration Biological Sample Microbial Changes Metabolite Changes Reference
30 Male
Sprague-Dawley Rats
Chondrus crispus
Whole Seaweed (WS)
0.5% (w/w)
2.5% (w/w) 21 days Faeces
↑Bifidobacterium ↑Legionella ↑Sutterella
↑Blautia ↑Holdemania
↑Shewanella ↑Agarivorans
↓Streptococcus
↑Bifidobacterium breve (2.5% WS)
↑ Acetate
↑ Propionate (2.5% WS)
↑ Butyrate
↑ Total SCFA
[15]
24 Male
Sprague-Dawley Rats
Ecklonia radiata Whole Seaweed
(WS)
Ecklonia radiata Polysaccharide
Fraction (PF)
5% (w/w) WS
5% (w/w) PF 7 days Caecum
↑F. prausnitzii ↑ E. coli (PF)
↓ Enterococcus (WS)
↓Lactobacillus ↓Bifidobacterium
↓ Firmicutes:Bacteroidetes
↑ Acetate
↑ Propionate
↑ Butyrate (PF)
↓ Valerate
↓ Hexanoate
↑ Total SCFA
↓ i-Butyrate
↓ i-Valerate
↓ phenol
↓ p-cresol
[129]
18 Male Wistar Rats
Alginate (A)
Laminarin (L)
Fucoidan (F)
2% (w/w) 14 days Caecum
↑ Bacteroides (Bacteroides capillosus)
Presence of Enterorhabdus (A)
↑ Proteobacteria. Presence of
Lachnospiracea, Parabacteroides
(Parabacteroides distasonis) and
Parasutterella (L)
Not fermented (F)
↑ Propionate (L)
↑ Total SCFA (A, L) [97]
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Table 7. Cont.
16 Male
C57 BL/6 Mice
Saccorhiza polyschides extract
(BAE)
High fat diet +
5% (w/w) BAE 8 months Faeces ↓ Faecal bile salt hydrolase activity ↓ Secondary bile acids [54]
18 Male Wistar Rats Alginate (A)Laminarin (L) 2% (w/w) 14 days Caecum
↑Lactobacillus ↑Porphyromonas
↑Coprobacillus
↑Oscillibacter valencigenes
↓ Parabacteroides (L)
↑ Catabacter honkongensis
↑ Stomatobaculum longum
↓ Adlercreuzia (A)
↓ Helicobacter (A, L)
↑ Lactic acid (L)
= Acetate
= Propionate
= Butyrate
= Total SCFA
↓ Indole
[130]
18 Male C57BL/6 mice
Ascophyllum nodosum Fucoidan
(FuA)
Laminaria
japonica Fucoidan (FuL)
100 mg/kg/day 6 weeks Caecum
↑Lactobacillus ↑Anaeroplasma
↑Thalassospira (FuA)
↑Ruminococcaceae ↓ Alistipes
↓ Clostridiales
↓ Akkermansia (FuL)
↓ Candidatus ↓ Arthromitus
↓ Peptococcus
↓ Lachnospiraceae Incertae Sedis (FuA,
FuL)
- [96]
15 Male Wistar rats
Ascophyllum nodosum seaweed
crude polysaccharide (SCP)
SCP Lactobacillus plantarum
hydrolysate (SCPH Lp)
SCP Enterococcus fecalis
hydrolysate (SCPH Ef)
Alginate (A)
Hydrolysed Alginate (HA)
0.2 g per 180
–200 g rat weight 4 days Faeces -
↑ Acetate (HA > A >
SCPH Lp > SCPH Ef)
↑ Propionate (HA = A =
SCPH Lp = SCPH Ef)
↑ Butyrate (HA = A =
SCPH Lp = SCPH Ef)
(relative to day zero)
[131]
32 Female Kunming
mice
Enteromorpha prolifera (EP)
Enteromorpha polysaccharide
extract (PEP)
1:5 (w/w) 7 days Faeces
↑Alpha diversity (EP)
↑Bacteroidales S24-7 (EP)
↑ Prevotellaceae (PEP)
↑ Firmicutes ↑Actinobacteria (EP,
PEP)
↓ Bacteroidetes ↓ Proteobacteria (EP,
PEP)
- [119]
SCFA, Short Chain Fatty Acid; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control.
Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the
seaweed substrates tested exerted the effect.
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3. Polyphenols
Seaweeds are rich in polyphenols, such as catechins, flavonols, and phlorotannins. Red and green
seaweeds are a source of bromophenols, phenolic acids, and flavonoids [132], while phlorotannins are
the most abundant polyphenol in brown seaweeds. Most research to date concerns the bioactivity of
phlorotannins, a class of polyphenol unique to brown algae comprised of phloroglucinol monomers
and categorised as eckols, fucols, fuhalols, ishofuhalols, phloroethols, or fucophloroethols [132].
The purported bioactivities of seaweed polyphenols are associated with the mitigation of risk factors
pertained to type 2 diabetes and cardiovascular disease, including hyperglycemia, hyperlipidemia,
inflammation and oxidative stress [133–137], and also anti-microbial activity [138]. Owing to
heterogeneity in both molecular weight and the level of isomerisation, characterisation of polyphenols
is difficult [139–141], and a paucity of information exists regarding the endogenous digestion and
microbial catabolism of seaweed polyphenols, with a scarce mechanistic understanding of how they
may exert health benefits via the gut microbiota.
Most polyphenols of plant origin must undergo intestinal biotransformation by endogenous
enzymes and the gut microbiota prior to absorption across enterocytes. These enzymatic transformations
include the elimination of glycosidic bonds, for example, flavonoids are converted to glycones (sugars)
and aglycones (non-sugars–polyphenols) by endogenous β-glucosidases in the small intestine [142].
The transport of aglycones to the liver via the portal vein results in phase II biotransformation
(coupling reactions, chiefly hepatic conjugation to O-glucuronides and O-sulfates) to facilitate
urinary and biliary elimination. Phase II metabolites are absorbed into the systemic circulation,
or excreted in bile and re-enter the duodenum (hepatic recycling), where subsequent glucuronidase,
glycosidase, or sulphatase-mediated deconjugation by the colonic microbiota may favour aglycone
reabsorption [143].
Approximately 90–95% of dietary polyphenols reach the colon intact [144], where biotransformation
and metabolism by the gut microbiota occurs via hydrolysis, reduction, decarboxylation, demethylation,
dehydroxylation, isomerisation, and fission [145], to produce low-molecular weight compounds
with less chemical heterogeneity than the polyphenol parent compound [142]. It is suggested that
a complex network of gut microbial species is necessary for full biotransformation of polyphenols,
whereas simple reactions, such as deglycosylation, can be achieved by individual gut strains.
Furthermore, the bioactivities associated with dietary polyphenol intake may be dependent on the
catabolic capacity and composition of the gut microbiota, owing to the biological activity of metabolites
rather than the parent polyphenol compound present in food [146,147], while a synergistic effect
between prebiotic polyphenols and probiotic bacteria may occur [6].
The identification of bacteria which possess the metabolic capabilities to utilise polyphenols
was previously identified in Eubacterium oxidoreducens, which could catabolise gallate, pyrogallol,
phloroglucinol and quercetin [148]. Quercetin biotransformation by Eubacterium ramulus has also
been identified [149], and multiple human gut microbes which possess phenolic enzymes capable of
breaking down glycosides, glucuronides, sulphates, esters, and lactones was summarised by Selma
et al. [145]. Such microorganisms included E. coli withβ-glucuronidase activity; Eubacterium, Bacteroides,
and Clostridium with β-glucosidase activity; Lactobacillus, Eubacterium, Clostridium , Butyrbacterium,
Streptococcus, and Methylotrophicum with demethylase activity; and E. coli, Bifidobacterium, Lactobacillus,
Bacteroides, Streptococcus , Ruminococcus, and Enterococcus with esterase activity. There is also
evidence for α-l-Rhamnosidase mediated hydrolysis of rutinose, present on glycosylated polyphenols
(rhamnoglycosides), to produce aglycones, by species, such as Bacteroides thetaiotaomicron [50],
Bifidobacterium dentium [150], Bifidobacterium catenulatum [151], Bifidobacterium pseudocatenulatum [151],
and Lactobacillus plantarum [152].
Current knowledge regarding the fate of seaweed polyphenols in the human gastrointestinal tract
is scarce; however, it is understood that the limited absorption of Ascophyllum nodosum polyphenols
from small intestinal enterocytes to the portal vein may facilitate the conjugation of polyphenols
to methylated, glucuronidated, or sulphated forms rather than hydrolysis to aglycones [153,154].
Mar. Drugs 2019, 17, 327 17 of 35
Subsequently, unabsorbed conjugated polyphenols are available for biotransformation by the colonic
microbiota, then potentially absorbed across the colonocytes. Indeed, Corona et al. [154], observed a
reduction of total polyphenol contents of an Ascophyllum nodosum polyphenol extract, high molecular
weight fraction (>10 kDa), and low molecular weight fraction (1–10 kDa) following in vitro digestion
and batch culture fermentation; although anti-genotoxic activity against H2O2 induced DNA damage of
HT-29 cells was increased (to a greater extent by the high molecular weight fraction). This study did not
assess the microbiota composition, however, elsewhere, an in vitro fermentation of an Ecklonia radiata
phlorotannin extract significantly increased Bacteroidetes, Clostridium coccoides, E. coli, and Fecalibacterium
prausnitzii, but decreased Bifidobacterium and Lactobacillus populations after 24 h fermentation [56].
More in vitro digestion studies would be useful to understand the stability of seaweed polyphenols as
extracts or within the seaweed matrix [155,156]. These studies may be complemented by studies which
use ileostomy patient cohorts to determine structural changes to seaweed polyphenols following upper
GI digestion in vivo to indicate polyphenol bioaccessibility in the colon [157].
A recent review highlighted the potential for dietary polyphenols to modulate the gut
microbiota by increasing Bifidobacterium, Lactobacillus, Bacteroides, Enterococcus, Akkermansia muciniphila,
and Fecalibacterium prausnitzii populations [158]. This review did not include any studies which
assessed modulation of the gut microbiota by seaweed polyphenols and, therefore, a research
opportunity is presented. Inter-individual variation of gut microbiota composition and function
is the key determinant for gut microbiota-mediated biotransformation of phenolic compounds to
bioactive metabolites [159,160]. Therefore, identification of bacterial species or strains with the ability
to catabolise seaweed polyphenols and their respective catabolic machinery is needed to understand if
seaweed polyphenols could be prebiotic [161,162]. Moreover, considering that gut microbiota-derived
secondary metabolites reach a peak plasma concentration much later than the original aglycone or
hepatic conjugates, controlled nutrikinetic studies could elude how dietary polyphenols from seaweeds
interact with host-microbiota metabolism [163,164]. Identification of faecal, urinary, serum, or tissue
biomarkers via untargeted and targeted metabolomics approaches, and the use of stable isotope studies,
may also indicate variation in synthesis, bioavailability, metabolism, and excretion of polyphenols
and associated metabolites. While integration of dose response studies alongside metagenomics
and metabolomics analyses, akin to those conducted for berry and wine polyphenols, could elude
how much seaweed polyphenol is required to have an impact, if any, on gut microbial composition,
metabolic function, and host health [165,166].
4. Other Seaweed Phytochemicals
4.1. Carotenoids
Carotenoids are lipid soluble compounds which function within the photosynthetic machinery of
seaweeds to produce pigments. Fucoxanthin is the predominant carotenoid in brown seaweeds [167],
while lutein, β-carotene, astaxanthin, echinenone, violaxanthin, neoxanthin, and zeaxanthin are
found in red and green seaweeds. Carotenoids are used as food colouring additives, while the
application of fucoxanthin as functional food ingredients is suggested, owing to putative anti-oxidant,
anti-inflammatory, anti-cancer, anti-obesity, and anti-diabetic bioactivities [168–173].
While some carotenoids are absorbed by enterocytes and converted into vitamin A and retinoid
derivatives by endogenous beta-carotene oxygenase 1 (BCO1) and beta-carotene dioxygenase 2
(BCO2) enzymes [174,175], the bioavailability of carotenoids in the blood is reported as 10−40% [176],
which has led to suggestions that carotenoids could be fermented by the gut microbiota [174,177].
The only evidence to date has demonstrated that male C57BL/6J mice supplemented with 0.04% (w/w)
astaxanthin during an eight-week pilot study had increased abundance of caecal Bifidobacterium [178],
whereas Proteobacteria and Bacteroides were significantly increased in the caecum of BCO2 knockout
mice; however, analysis of health biomarkers was not reported. Given the differences in microbiota
composition between wild type and BCO2 knockout mice in this study, there is scope to investigate
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how carotenoids and their endogenous derivatives interact with the gut microbiota. Looking ahead,
the use of in vitro models of gastrointestinal digestion and colonic fermentation would be useful to
assess whether there is a direct substrate to microbiota effect or a host–microbe effect [179].
4.2. Polyunsaturated Fatty Acids (PUFAs)
The lipid content of seaweed ranges from 1–5% dry weight, which includes n-3 PUFAs, such as
eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA) [180,181]. The n-3 PUFA are associated
with the anti-inflammatory activity to reduce cardiovascular disease risk and may also exert beneficial
effects on brain function and behaviour, as mediated by the microbiota-gut-brain axis [182]. Dietary EPA
and DHA intake are reported to improve microbial diversity, reduce the Firmicutes/Bacteroidetes
ratio, reduce LPS-producing bacteria, and increase populations of Bifidobacterium, Lachnospiraceae,
and lipopolysaccharide (LPS)-suppressing bacteria in both humans and animal models [182–184].
Although the evidence to date has focused on fish-derived n-3 PUFA, great scope exists to evaluate the
prebiotic effect of n-3 PUFA obtained from seaweeds.
5. Fermented Foods
Fermented foods are understood to have improved nutritional and functional properties owing to
bioactive or bioavailable components [185]. Seaweeds (mainly kelp) are a common vegetable ingredient
in the fermented food, Kimchi. The microbial content of kimchi provides a source of probiotics, nutrients,
and bioactive metabolites, which are reported to have anti-microbial, anti-oxidant, and anti-obesogenic
activities [186–188]. One randomised controlled trial (RCT) observed that consumption of a seaweed
Kimchi made from L. japonica for four weeks promoted the growth and survival of gut microbial lactic
acid bacteria in humans [189], whilst another RCT concluded that consumption of 1.5 g/day fermented
L. japonica containing 5.56% γ-aminobutyric acid (GABA) (Lactobacillus brevis BJ2 culture) was associated
with a reduction in oxidative stress in healthy adults over four weeks, indicated by decreased serum
γ-glutamyltransferse (GGT) and malondialdehyde, and increased antioxidant activity of superoxide
dismutase and catalase compared to the placebo [190]. The latter study indicates that foods containing
fermented brown seaweeds, such as L. japonica, may offer a novel source of GABA enriched ingredients,
which are associated with hypotensive and anti-inflammatory effects [188]. Anti-oxidant, anti-diabetic,
and anti-hypertensive efficacies are also reported for Korean rice wine fermented with L. japonica [191],
while Sargassum fermented with a starter culture of Enterococcus faecium was reported to contain higher
soluble polyphenol and mannuronic acid-rich alginate contents [192], which may increase the provision
of microbiota accessible components for colonic fermentation.
Reports of the functional properties of fermented foods containing red seaweeds are scarce;
however, examples of red seaweed fermented foods include a fermented Porphyra yezoensis seaweed
sauce, which used the marine halophilic lactic acid bacteria, Tetragenococcus halophilus, as a starter
culture [193]; a Gracilaria domingensis aqueous extract applied as a texture modifier in fermented milks
as a non-animal alternative to gelatin [194]; and carrageenan as a salt replacer in the production of
fat-free cheese [195].
Given the availability of red, brown, and green seaweeds both commercially and locally [196],
the production of seaweed-containing fermented foods could be a cost-effective alternative to bioactive
component extraction. Nevertheless, an understanding of how live bacteria and bacterial metabolites
present in fermented foods contribute towards health is required [185].
6. Seaweeds and Animal Health
Seaweeds also have a historical use as animal feed ingredients [197]. The capacity for seaweeds
to modulate the gut microbiota of monogastrics, such as pigs and hens, is presented in Tables 8
and 9, respectively, which complements the recent evidence for the application of seaweed bioactives
in monogastric animal feed [198]. Table 8 shows limited evidence that the β-glucan, laminarin,
may increase Lactobacillus populations but not Bifidobacterium populations. While there is scarce
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evidence for the selective stimulation of health-associated bacteria in pigs by the sulphated fucose,
fucoidan. Only one recent study has evaluated the effect of dietary alginate on the porcine microbiota,
where the genera Ruminococcus, Roseburia and Lachnospira, and an unclassified bacterium of the F16
family were increased, alongside a significant decrease in the genus Blautia, the family Clostridiaceae,
and an unclassified bacterium of RF39 family [199]. In Table 9, recent evidence indicates that hens fed
Chondrus crispus and Sarcodiotheca gaudichaudii red seaweeds may increase ceacal SCFA concentrations
and modulate populations of Bifidobacterium longum, Lactobacillus acidophilus, Streptococcus salivarius,
and Clostridium perfringens [200,201]; however, a bidirectional change in microbial composition was
dose dependent and has only been assessed in two studies to date. Given the use of pigs as an animal
model of humans [202], data from in vivo monogastric studies which are designed to evaluate the
prebiotic potential of dietary seaweeds and seaweed-derived components could provide insight into
the potential for human applications.
Tables 10 and 11 summarise recent studies which have examined the impact of seaweed diets on
the ruminant microbiota of cows and sheep, respectively, with the potential application of reducing
methane production. Despite demonstrating decreased methane production, the cow rumen in vitro
fermentation studies presented in Table 10 did not assess microbiota compositional changes, thus a
knowledge gap is presented to understand which bacteria (if any), are increased or decreased, and are
associated with a reduction in methane production. Table 11 shows that methanogenic bacteria
and methane production were significantly decreased compared to the basal grass substrate control
following the in vitro fermentation of sheep rumen with the red seaweed Asparagopsis taxiformis [203].
While sheep given an ad libitum diet of Ascophyllum nodosum brown seaweed (1%, 3%, or 5%
w/w) for 21 days demonstrated a dose-dependent decrease in propionate and butyrate SCFAs and
a dose-dependent increase in acetate [204], while several bacteria were significantly decreased,
including Prevotella copri, Roseburia, and Coprococcus, while Blautia producta and the family Veillonellaceae
were significantly increased compared to the basal diet. Moreover, the specific case of seaweed-fed
North Ronaldsay sheep highlights how isolated organisms of the ruminant microbiome, such as
Prevotella, Clostridium butyricum, Butyrivibrio fibrisolvens, and Spirochaetes have adapted to hydrolyse
alginate laminarin, and fucoidan [205,206]. However, there is a paucity of evidence to implicate any
health benefits attributed to a seaweed diet in these animals.
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Table 8. Impact of seaweeds on the porcine gut microbiota.
Animal Seaweed Component Dose Duration Biological Sample Microbial Changes Metabolite Changes Reference
20 pregnant gilts
and 48 piglets
Laminarin/Fucoidan
Extract 10 g/day
Gestation (day 83)
to weaning
(day 28)
Faeces (Sow)
Colonic digesta
(Piglet)
Sows (parturition): ↓
Enterobacteriaceae
= Lactobacilli
Piglets (birth, 48h after birth,
weaning):
= Enterobacteriaceae = Lactobacilli
- [207]
200 pigs Ecklonia cava WholeSeaweed
0.05% (w/w)
0.1% (w/w)
0.15% (w/w)
28 days Caecum
↑Lactobacillus
↓ E. coli
= Total Anaerobes
- [208]
24 pigs
Laminarin/Fucoidan
Extract (SD)
Laminarin/Fucoidan
Wet Seaweed (WS)
5.37 Kg/tonne SD
26.3 Kg/tonne WS 21 days
Ileum
Caecum
Colon
= Bifidobacteria
= Lactobacillus
= Enterobacterium (SD, WS)
↑Lactobacillus agilis (colon)
- [209]
48 pigs Laminarin Extract 300 ppm 32 days Faeces ↑Lactobacillus
= Bifidobacteria
= Acetate
↓ Propionate
= Butyrate
= Valerate
= i-Butyrate
= i-Valerate
[210]
48 pigs β-glucan 250 g/tonne150 g/tonne 29 days
Ileum
Caecum
Proximal Colon
Distal Colon
= Lactobacilli
= Bifidobacteria.
↑ Lactobacillus diversity
- [211]
168 pigs Laminarin (L)Fucoidan (F)
240 mg/kg F
150 mg/kg L
300 mg/kg L
150 mg/kg L and
240 mg/kg F
300 mg/kg L and
240 mg/kg F
35 days Faeces
= E. coli
= Bifidobacteria
↑ Lactobacilli
= Acetate
= Propionate
= Butyrate
= Valerate
= i-Butyrate
= i-Valerate
= Total SCFA
[212]
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Table 8. Cont.
9 pigs Alginate 5.14% (w/w) 84 days Faeces
= Diversity
↑ Unclassified F16 family
↓ Clostridiaceae
↓ Unclassified RF39 (Mollicutes)
↑ Ruminococcus
↑ Roseburia
↑ unclassified F16 genus (TM7)
↑ Lachnospira
↓ Blautia
- [199]
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with
abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
Table 9. Impact of seaweeds on the hen gut microbiota.
Animal Seaweed Component Dose Duration Biological Sample Microbial Changes MetaboliteChanges Reference
160 laying hens
Chondrus crispus
Whole Seaweed (CC)
Sarcodiotheca
gaudichaudii
Whole Seaweed (SG)
0.5% (w/w)
1% (w/w)
2% (w/w)
30 days IleumCaecal digesta
↑Bifidobacterium longum (CC2,
SG1, SG2)
↑Streptococcus salivarius (CC1,
CC2, SG2)
↓Clostridium perfringens (CC1,
CC2, SG1, SG2)
↓Lactobacillus acidophilus (CC1,
CC2)
↑ Acetate (CC1,
SG1)
↑ Propionate (CC2)
↑ Butyrate (SC2)
[200]
96 laying hens
Chondrus crispus
Whole Seaweed (CC)
Sarcodiotheca
gaudichaudii
Whole Seaweed (SG)
Control diet
+ 2% (w/w)
seaweed
Control diet
+ 4% (w/w)
seaweed
28 days Caecum
↑Lactobacillus acidophilus (CC4)
↓Bifidobacterium longum (SG2,
SG4, CC4)
↓ Streptococcus salivarius (SG2,
SG4, CC2, CC4)
↑ Bacteroidetes (SG4, CC2, CC4)
↑ Propionate (CC4) [201]
=, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with
abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
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Table 10. In vitro fermentation of seaweeds with cow rumen inoculum.
Seaweed Substrate ExperimentalParameters Dose (w/v)
Microbial
Enumeration
Microbial
Changes
Metabolomics
Analysis
Technique
Metabolite Changes Reference
Ascophyllum nodosum
(AN)
Laminaria digitata (LD)
Whole Seaweed
50% pooled inoculum
(n = 4)
24 h
0.5 g/L
1 g/L
2 g/L
- - GC-FID
↑Propionate
↑Butyrate (LD)
↓ BCFA
↓Methane
[213]
Asparagopsis taxiformis Whole Seaweed
20% pooled inoculum
(n = 4)
72 h
0.5%
1%
2%
5%
10%
- - GC-FID
↓ Total gas production
↓Methane
↓ Acetate
↑ Propionate
↑ Butyrate (2%, 10%)
↓ Total SCFA (5%, 10%)
[214]
Ulva sp.
Laminaria ochroleuca
Saccharina latissima
Gigartina sp.
Gracilaria vermiculophylla
Whole Seaweed
20% pooled inoculum
(n = 2)
24 h
25% - - GC-FID ↓Methane [215]
Brown seaweed
by-products (BSB) -
50% (v/v)
single inoculum
0, 3, 6, 9, 12, and 24 h
2%
4% - - GC-FID
↓ Ammonia (3, 9, 12 and
24 h)
↓ Total SCFA (24 h)
[216]
GC-FID, Gas Chromatography; =, no statistical difference compared to the control; ↑, significant increase compared to the control; ↓ significant decrease compared to the control.
Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the effect. If no abbreviations in parenthesis are presented, then all of the
seaweed substrates tested exerted the effect.
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Table 11. Impact of seaweeds on the sheep rumen microbiota.
Seaweed Dose Experimental Parameters MicrobialEnumeration Microbial Changes
Metabolomics
Analysis Technique Metabolite Changes Reference
Asparagopsis
taxiformis
Whole Seaweed
2%
in vitro batch culture
fermentation
20% (v/v) pooled sheep rumen
fluid inoculum (n = 4)
48 and 72 h
16S rRNA NGS
qPCR
↓Methanogens
↓Bacteroidetes/Firmicutes
ratio
↓mcrA gene expression
GC-MS
↓ Total Gas
↓Methane
↑ Hydrogen
[203]
Ascophyllum
nodosum
Whole Seaweed
1%
3%
5%
Rams (n = 8)
21 days ad libitum 16S rRNA NGS
↓ undefined TM7-1
↓undefined Coriobacteriaceae
↓Roseburia
↓Coprococcus
↓Prevotella copri
↑Blautia producta
↑ Entodinium species 1
↑Veillonellaceae
GC-FID
Dose dependent:
↑ Acetate
↓ Propionate
↓ Butyrate
PICRUSt:
↑Butanoate metabolism
↑ Fatty acid metabolism
↓Glycerophospholipid
metabolism
[204]
16S rRNA NGS, 16S rRNA Next Generation Sequencing; qPCR, Quantitative PCR; GC-FID, Gas Chromatography; =, no statistical difference compared to the control; ↑, significant increase
compared to the control; ↓ significant decrease compared to the control. Microbial and metabolite changes with abbreviations in parenthesis indicate the substrate(s) which exerted the
effect. If no abbreviations in parenthesis are presented, then all of the seaweed substrates tested exerted the effect.
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7. Conclusions
Current evidence regarding the prebiotic effects of seaweeds is dominated by complex
polysaccharide components. This is because prebiotic research was previously focused on saccharolytic
fermentation by the gut microbiota. Accumulating evidence from in vitro and in vivo animal studies
provides encouraging data regarding the utilisation of red seaweed galactans and brown seaweed
glycans, such as alginates and laminarins, with minor evidence for fucoidan and the green seaweed
polysaccharide, ulvan.
Given that the most recent definition of prebiotic places non-complex polysaccharide
components in vogue, an opportunity is presented to explore how other seaweed phytochemicals,
including polyphenols, carotenoids, and PUFAs, are metabolised by host microbial populations to
benefit host health. Future investigations should consider the use of in vitro screening studies and
in vivo animal studies to identify putative prebiotic compounds from seaweeds via the identification
of host organisms which utilise seaweed components and the bioactive metabolites produced
(via untargeted metabolomics). Furthermore, controlled human intervention studies with health-related
end points to elucidate prebiotic efficacy are required.
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